Cosmo Pharmaceuticals N.V (C43) — Cash Flow Reinvestment Rate
Cosmo Pharmaceuticals N.V (C43) has a Cash Flow Reinvestment Rate of 3.04x as of June 2022, reinvesting €19.08 Million (capex €1.11 Million plus investments €17.98 Million) from operating cash flow of €6.28 Million. See Cosmo Pharmaceuticals N.V (C43) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Cosmo Pharmaceuticals N.V Cash Flow Reinvestment Rate (2016–2024)
Historical reinvestment intensity for Cosmo Pharmaceuticals N.V across 6 annual periods. For the full cash flow conversion analysis, see cash flow conversion of Cosmo Pharmaceuticals N.V.
Annual Cash Flow Reinvestment Rate for Cosmo Pharmaceuticals N.V (2016–2024)
Year-by-year capital reinvestment analysis for Cosmo Pharmaceuticals N.V. See Cosmo Pharmaceuticals N.V (C43) flexibility index to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (EUR) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 0.79x | €129.11 Million | €162.41 Million | €5.65 Million | ▼ -53.6% |
| 2023 | 1.71x | €57.61 Million | €33.62 Million | €15.31 Million | ▲ +532.7% |
| 2022 | 0.27x | €9.00 Million | €33.23 Million | €7.31 Million | ▼ -72.1% |
| 2021 | 0.97x | €12.22 Million | €12.61 Million | €5.49 Million | ▼ -88.7% |
| 2020 | 8.59x | €111.60 Million | €12.98 Million | €4.12 Million | ▲ +217.9% |
| 2016 | 2.70x | €58.65 Million | €21.69 Million | €18.43 Million | — |